BG107874A - Използване на апоморфин за лечение на сексуално разстройство, предизвикано от антидепресивно лекарство - Google Patents

Използване на апоморфин за лечение на сексуално разстройство, предизвикано от антидепресивно лекарство Download PDF

Info

Publication number
BG107874A
BG107874A BG107874A BG10787403A BG107874A BG 107874 A BG107874 A BG 107874A BG 107874 A BG107874 A BG 107874A BG 10787403 A BG10787403 A BG 10787403A BG 107874 A BG107874 A BG 107874A
Authority
BG
Bulgaria
Prior art keywords
apomorphine
use according
hydrochloride
patient
therapeutically effective
Prior art date
Application number
BG107874A
Other languages
Bulgarian (bg)
English (en)
Inventor
Dustin D. Ruff
Renee J. Perdok
Original Assignee
Tap Pharmaceutical Products Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tap Pharmaceutical Products Inc. filed Critical Tap Pharmaceutical Products Inc.
Publication of BG107874A publication Critical patent/BG107874A/bg

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Gynecology & Obstetrics (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
BG107874A 2000-11-15 2003-06-04 Използване на апоморфин за лечение на сексуално разстройство, предизвикано от антидепресивно лекарство BG107874A (bg)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US24903100P 2000-11-15 2000-11-15
PCT/US2001/043933 WO2002039879A2 (en) 2000-11-15 2001-11-14 Treatment of anti-depression drug-induced sexual dysfunction with apomorphine

Publications (1)

Publication Number Publication Date
BG107874A true BG107874A (bg) 2004-01-30

Family

ID=22941748

Family Applications (1)

Application Number Title Priority Date Filing Date
BG107874A BG107874A (bg) 2000-11-15 2003-06-04 Използване на апоморфин за лечение на сексуално разстройство, предизвикано от антидепресивно лекарство

Country Status (18)

Country Link
US (1) US6528521B2 (ja)
EP (1) EP1341536A4 (ja)
JP (1) JP2004513899A (ja)
KR (1) KR20030077538A (ja)
CN (1) CN1486183A (ja)
AU (1) AU2002235129A1 (ja)
BG (1) BG107874A (ja)
BR (1) BR0111982A (ja)
CA (1) CA2429047A1 (ja)
CZ (1) CZ20031540A3 (ja)
HU (1) HUP0302436A3 (ja)
IL (1) IL155667A0 (ja)
MX (1) MXPA03004288A (ja)
NO (1) NO20032189L (ja)
PL (1) PL361875A1 (ja)
SK (1) SK7422003A3 (ja)
WO (1) WO2002039879A2 (ja)
ZA (1) ZA200303471B (ja)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6787532B2 (en) * 2000-08-05 2004-09-07 Smithkline Beecham Corporation Formulation containing anti-inflammatory androstane derivatives
US20040204439A1 (en) * 2003-04-14 2004-10-14 Staniforth John Nicholas Composition, device, and method for treating sexual dysfunction via inhalation
AU2004228757A1 (en) * 2003-04-14 2004-10-21 Vectura Ltd Pharmaceutical compositions comprising apomorphine for pulmonary inhalation
ES2426915T3 (es) 2003-09-10 2013-10-25 Brentwood Equities Ltd. Diastereoisómeros de 4-ariloxi-3-hidroxipiperidinas
GB0425758D0 (en) 2004-11-23 2004-12-22 Vectura Ltd Preparation of pharmaceutical compositions
GB0721394D0 (en) * 2007-10-31 2007-12-12 Vectura Group Plc Compositions for trating parkinson's disease
CA3116942A1 (en) 2010-12-16 2012-06-21 Sunovion Pharmaceuticals Inc. Sublingual films comprising apomorphine and an organic base
WO2014105655A1 (en) 2012-12-24 2014-07-03 Neurogastrx, Inc. Methods for treating gi tract disorders
CA3127926A1 (en) 2015-04-21 2016-10-27 Sunovion Pharmaceuticals Inc. Methods of treating parkinson's disease by administration of apomorphine to an oral mucosa
WO2017168174A1 (en) 2016-04-02 2017-10-05 N4 Pharma Uk Limited New pharmaceutical forms of sildenafil
BR112020014598A2 (pt) 2018-01-18 2020-12-08 Leukos Biotech, S. L. Forma cristalina de partículas sólidas cocristalinas de apomorfina·ácido palmítico
US11717495B2 (en) * 2020-03-16 2023-08-08 Vella Bioscience, Inc. Use of cannabinoids in treating anti-depressant-induced female sexual dysfunction
US10836757B1 (en) 2020-04-02 2020-11-17 Neurogastrx, Inc. Polymorphic forms of metopimazine
CN115671106B (zh) * 2021-07-21 2024-03-19 广州新济药业科技有限公司 吗啡的应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4521421A (en) * 1983-09-26 1985-06-04 Eli Lilly And Company Treatment of sexual dysfunction
ES2194867T3 (es) * 1993-03-26 2003-12-01 Franciscus Wilhelmus He Merkus Composiciones farmaceuticas para la administracion intranasal de apomorfina.
KR100374924B1 (ko) 1994-04-22 2003-07-22 퀸스 유니버시티 엣 킹스톤 남성발기기능장애를회복시키고진단하기위한설하용량형
US5562917A (en) 1994-12-23 1996-10-08 Pentech Pharmaceuticals, Inc. Transdermal administration of apomorphine
US5888534A (en) * 1995-06-13 1999-03-30 Pentech Pharmaceuticals, Inc. Controlled release of drugs delivered by sublingual or buccal administration
ATE211906T1 (de) 1996-03-12 2002-02-15 Alza Corp Zusammensetzung und dosisform mit einem opioid- antagonisten
US5897864A (en) 1996-05-23 1999-04-27 Cohen; Alan J. Method for treating sexual dysfunction disorders with compositions containing ginkgo biloba
JP2001504851A (ja) * 1996-12-02 2001-04-10 メルク シヤープ エンド ドーム リミテツド 性的機能不全の治療のためのｎｋ−１受容体拮抗薬の使用
US5945117A (en) 1998-01-30 1999-08-31 Pentech Pharmaceuticals, Inc. Treatment of female sexual dysfunction
US6399826B1 (en) * 1999-08-11 2002-06-04 Sepracor Inc. Salts of sibutramine metabolites, methods of making sibutramine metabolites and intermediates useful in the same, and methods of treating pain

Also Published As

Publication number Publication date
PL361875A1 (en) 2004-10-04
CZ20031540A3 (cs) 2004-05-12
US20020115683A1 (en) 2002-08-22
SK7422003A3 (en) 2004-01-08
CN1486183A (zh) 2004-03-31
ZA200303471B (en) 2004-08-06
MXPA03004288A (es) 2004-09-10
HUP0302436A3 (en) 2004-10-28
NO20032189L (no) 2003-07-08
CA2429047A1 (en) 2002-05-23
EP1341536A2 (en) 2003-09-10
US6528521B2 (en) 2003-03-04
HUP0302436A2 (hu) 2003-11-28
EP1341536A4 (en) 2007-08-01
BR0111982A (pt) 2003-10-28
WO2002039879A3 (en) 2002-07-25
JP2004513899A (ja) 2004-05-13
KR20030077538A (ko) 2003-10-01
WO2002039879A2 (en) 2002-05-23
NO20032189D0 (no) 2003-05-14
AU2002235129A1 (en) 2002-05-27
IL155667A0 (en) 2003-11-23

Similar Documents

Publication Publication Date Title
JP5550101B2 (ja) トラマドールの副作用の低減薬の製造におけるトラマドールおよびｐｄｅ阻害剤の使用方法
KR100719977B1 (ko) 성기능 장애 치료를 위하여 효과 발현이 신속한 선택적 세로토닌 재흡수 억제제를 사용하는 방법
BG107874A (bg) Използване на апоморфин за лечение на сексуално разстройство, предизвикано от антидепресивно лекарство
US6506765B2 (en) Apomorphine derivatives and methods for their use
EP1164848A1 (en) Compositions and methods for preventing and treating sexual dysfunctions
KR20010101241A (ko) 남성의 기질적 발기 부전 치료용 약제의 제조시아포모르핀의 용도
AU749703B2 (en) Combination therapy for modulating the human sexual response
US20020006933A1 (en) Method for treating sexual dysfunction with apomorphine at specified plasma concentration levels
US20020086876A1 (en) Treatment of anti-depression drug-induced sexual dysfunction with apomorphine
US20100311785A1 (en) Combination Therapy For Modulating The Human Sexual Response
JP2004292316A (ja) アルツハイマー型痴呆の日常生活動作能力改善剤